CN105407912A - Adamts13的皮下施用 - Google Patents

Adamts13的皮下施用 Download PDF

Info

Publication number
CN105407912A
CN105407912A CN201480027202.3A CN201480027202A CN105407912A CN 105407912 A CN105407912 A CN 105407912A CN 201480027202 A CN201480027202 A CN 201480027202A CN 105407912 A CN105407912 A CN 105407912A
Authority
CN
China
Prior art keywords
adamts13
mammal
administered
hours
methods according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480027202.3A
Other languages
English (en)
Chinese (zh)
Inventor
N·A·希弗兹
W·赫尔里格尔
B·普莱莫厄
H·罗滕斯滕
E-M·穆欣契
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Bucks Elta Co ltd
Buck Elta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bucks Elta Co ltd, Buck Elta filed Critical Bucks Elta Co ltd
Priority to CN202111631652.1A priority Critical patent/CN114259558A/zh
Publication of CN105407912A publication Critical patent/CN105407912A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201480027202.3A 2013-03-15 2014-03-13 Adamts13的皮下施用 Pending CN105407912A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111631652.1A CN114259558A (zh) 2013-03-15 2014-03-13 Adamts13的皮下施用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794659P 2013-03-15 2013-03-15
US61/794,659 2013-03-15
PCT/US2014/026747 WO2014151968A1 (en) 2013-03-15 2014-03-13 Subcutaneous administration of adamts13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111631652.1A Division CN114259558A (zh) 2013-03-15 2014-03-13 Adamts13的皮下施用

Publications (1)

Publication Number Publication Date
CN105407912A true CN105407912A (zh) 2016-03-16

Family

ID=50549463

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480027202.3A Pending CN105407912A (zh) 2013-03-15 2014-03-13 Adamts13的皮下施用
CN202111631652.1A Pending CN114259558A (zh) 2013-03-15 2014-03-13 Adamts13的皮下施用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111631652.1A Pending CN114259558A (zh) 2013-03-15 2014-03-13 Adamts13的皮下施用

Country Status (18)

Country Link
US (4) US9611467B2 (https=)
EP (2) EP2968483B1 (https=)
JP (4) JP6484216B2 (https=)
KR (5) KR102513872B1 (https=)
CN (2) CN105407912A (https=)
AU (5) AU2013203062C1 (https=)
BR (1) BR112015023542A8 (https=)
CA (1) CA2905058A1 (https=)
DK (1) DK2968483T3 (https=)
EA (2) EA034546B1 (https=)
ES (1) ES2906550T3 (https=)
IL (3) IL241305B (https=)
MX (2) MX380485B (https=)
PL (1) PL2968483T3 (https=)
PT (1) PT2968483T (https=)
SG (3) SG11201507271QA (https=)
TW (4) TW202313664A (https=)
WO (1) WO2014151968A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115836126A (zh) * 2020-04-02 2023-03-21 武田药品工业株式会社 Adamts13变体、组合物及其用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
IL264372B2 (en) 2016-08-04 2024-05-01 Baxalta Inc Adamts13 for use in treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease
WO2020214033A1 (en) * 2019-04-17 2020-10-22 Erasmus University Medical Center Rotterdam Papain-like cysteine peptidase medicaments and uses thereof
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
CN115835904A (zh) * 2020-05-22 2023-03-21 武田药品工业有限公司 用于治疗和诊断冠状病毒疾病并发症的adamts13组合物和方法
WO2021242092A1 (en) * 2020-05-25 2021-12-02 Sanquin Innovatie B.V. Adamts13 protein variants and uses thereof
US20230405096A1 (en) * 2020-11-18 2023-12-21 Green Cross Corporation Adamts13 variant having increased escaping rate or activity against autoantibody
GB202102208D0 (en) * 2021-02-17 2021-03-31 Univ Manchester Adamts13 variant
WO2024151093A1 (ko) * 2023-01-11 2024-07-18 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물
JPWO2024224687A1 (https=) 2023-04-25 2024-10-31

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
CN1777809A (zh) * 2003-04-22 2006-05-24 巴克斯特国际有限公司 抗von Willebrand因子裂解的蛋白酶(ADAMTS13)抗体的诊断检测
WO2006133955A1 (en) * 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
WO2009140140A1 (en) * 2008-05-12 2009-11-19 Immune Disease Institute Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2012006591A1 (en) * 2010-07-08 2012-01-12 Baxter International Inc. METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE
CN102573792A (zh) * 2009-09-21 2012-07-11 巴克斯特国际公司 稳定化的液体和冻干的adamts13制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2009539757A (ja) * 2006-06-16 2009-11-19 バクスター・インターナショナル・インコーポレイテッド 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
CN1777809A (zh) * 2003-04-22 2006-05-24 巴克斯特国际有限公司 抗von Willebrand因子裂解的蛋白酶(ADAMTS13)抗体的诊断检测
WO2006133955A1 (en) * 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
WO2009140140A1 (en) * 2008-05-12 2009-11-19 Immune Disease Institute Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
CN102573792A (zh) * 2009-09-21 2012-07-11 巴克斯特国际公司 稳定化的液体和冻干的adamts13制剂
WO2012006591A1 (en) * 2010-07-08 2012-01-12 Baxter International Inc. METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115836126A (zh) * 2020-04-02 2023-03-21 武田药品工业株式会社 Adamts13变体、组合物及其用途

Also Published As

Publication number Publication date
US20140271611A1 (en) 2014-09-18
US9611467B2 (en) 2017-04-04
MX2015012783A (es) 2016-04-28
EA034546B1 (ru) 2020-02-19
AU2020202738A1 (en) 2020-05-14
AU2022211908A1 (en) 2022-09-01
BR112015023542A2 (pt) 2017-07-18
US11779635B2 (en) 2023-10-10
JP2016517421A (ja) 2016-06-16
WO2014151968A8 (en) 2015-10-15
KR102218489B1 (ko) 2021-02-22
KR102102087B1 (ko) 2020-04-20
JP6484216B2 (ja) 2019-03-13
IL273365B (en) 2022-05-01
CA2905058A1 (en) 2014-09-25
KR102513872B1 (ko) 2023-03-27
KR20220027266A (ko) 2022-03-07
ES2906550T3 (es) 2022-04-19
MX380485B (es) 2025-03-12
KR20210021107A (ko) 2021-02-24
TWI740207B (zh) 2021-09-21
KR20160016756A (ko) 2016-02-15
EP2968483B1 (en) 2021-12-01
TW201513881A (zh) 2015-04-16
US10413600B2 (en) 2019-09-17
IL290486B2 (en) 2023-08-01
AU2013203062A1 (en) 2014-10-02
US20200101144A1 (en) 2020-04-02
JP6998333B2 (ja) 2022-02-10
US11185575B2 (en) 2021-11-30
AU2018203665A1 (en) 2018-06-14
SG11201507271QA (en) 2015-10-29
KR20190022926A (ko) 2019-03-06
AU2013203062C1 (en) 2018-06-28
EA201591758A1 (ru) 2016-03-31
AU2022211908B2 (en) 2023-11-30
EP2968483A1 (en) 2016-01-20
IL273365A (en) 2020-05-31
NZ749570A (en) 2020-11-27
AU2013203062B2 (en) 2016-06-23
KR102365936B1 (ko) 2022-02-23
US20220080032A1 (en) 2022-03-17
TWI690326B (zh) 2020-04-11
EP3960196A1 (en) 2022-03-02
AU2016231547A1 (en) 2016-10-06
KR20200041394A (ko) 2020-04-21
IL290486B1 (en) 2023-04-01
TWI786563B (zh) 2022-12-11
CN114259558A (zh) 2022-04-01
TW202138003A (zh) 2021-10-16
JP2022027991A (ja) 2022-02-14
IL290486A (en) 2022-04-01
JP7238088B2 (ja) 2023-03-13
IL241305A0 (en) 2015-11-30
HK1220131A1 (zh) 2017-04-28
NZ751610A (en) 2020-11-27
JP2023071821A (ja) 2023-05-23
MX2021002513A (es) 2021-04-28
PT2968483T (pt) 2022-02-23
DK2968483T3 (da) 2022-02-14
JP2019142850A (ja) 2019-08-29
US20170224785A1 (en) 2017-08-10
PL2968483T3 (pl) 2022-04-04
NZ712440A (en) 2020-11-27
TW202313664A (zh) 2023-04-01
TW202017591A (zh) 2020-05-16
EA201591758A8 (ru) 2017-03-31
AU2018203665B2 (en) 2020-01-30
IL241305B (en) 2020-04-30
AU2016231547B2 (en) 2018-03-15
EA201992832A1 (ru) 2020-05-31
SG10201707074TA (en) 2017-10-30
SG10202001227QA (en) 2020-03-30
BR112015023542A8 (pt) 2019-12-03
AU2020202738B2 (en) 2022-06-09
WO2014151968A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
AU2022211908B2 (en) Subcutaneous administration of adamts13
HK40069281A (en) Subcutaneous administration of adamts13
HK1220131B (en) Subcutaneous administration of adamts13
NZ712440B2 (en) Subcutaneous administration of adamts13
NZ749570B2 (en) Subcutaneous administration of adamts13
NZ751610B2 (en) Subcutaneous administration of adamts13

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Illinois State

Applicant after: Hundred deep company

Applicant after: Hundred deep limited liability company

Address before: Illinois State

Applicant before: BAXALTA INC

Applicant before: BAXALTA GMBH

COR Change of bibliographic data
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210705

Address after: Osaka

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Illinois, USA

Applicant before: Baishen Co.

Applicant before: BAXALTA GmbH

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160316